4CPS-143 Real-world persistence of anti-iL5 therapies in uncontrolled asthma

<h3>Background and Importance</h3> IL-5 signalling is a target in asthma, and has yielded three monoclonal antibodies: mepolizumab, reslizumab and benralizumab. Little is known about persistence of asthma anti-IL5 biologic use in clinical practice. <h3>Aim and Objectives</h3> The objective of the study was to analyse the real-world persistence with anti-iL5 drugs over time in the treatment of uncontrolled asthma and reasons of treatment discontinuation. <h3>Material and Methods</h3> Observational, retrospective study that included all patients with uncontrolled asthma treated with mepolizumab, benralizumab or reslizumab. Variables collected were age, sex, anti-IL5 drug, length of treatment and reasons for treatment discontinuation. Outcome variable was percentage of treatments that reached 12-, 24- and 36-months persistence estimated from the first to the last drug dispensation, using the Kaplan-Meier method. Follow-up was carried out until September 2024. Treatment persistence was defined by the length of time that a person continuously used an asthma biologic. <h3>Results</h3> A total of 217 patients were analysed, 71% women, mean age was 60,4 years. 93 patients received mepolizumab, 80 benralizumab and 44 reslizumab. Persistence results at 12, 24 and 36 motnhs are shown in table 1. At the end of follow-up 88 (40,5%) treatments had finished. Percentages and reasons of drug discontinuation are shown in table 2. <h3>Conclusion and Relevance</h3> At 12 months all anti-IL5 persistence rates were high and reached 80%. Benralizumab seems to have better persistence rates at 36 months. Reslizumab persistence rates are influenced by drug shortage. Treatment with anti-IL5 drugs was generally well tolerated with low rate of discontinuation due to adverse reactions. A limitation is the high percentage of censored data. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest